Many experts in genetics and genomics believe that some – or all – of the above reflections are true of today’s personalized medicine. It’s easy to see how some of them apply. With technology advancing rapidly and the cost of sequencing dropping precipitously, we’re certainly experiencing the best of times in terms of our ability to explore the mysteries of the human genome. But our ability to store and interpret data still lags behind, and the more we hype the “personalized medicine revolution,” the more patients expect miracles that simply aren’t achievable. So how can we approach precision medicine from a balanced perspective? How can we optimize our resources and abilities to best serve our patients? Precision medicine is growing at an astounding pace – in the last decade, over 100 prominent new personalized diagnostic and treatment products have become available, and the Personalized Medicine Coalition has expanded more than tenfold. Even the President of the United States has launched a new Precision Medicine Initiative that funds not only grants, but the assembly of patient cohorts and the establishment of better regulatory standards. It’s clear the concept is catching on, so how can research and clinical laboratories get on board? We spoke with the leaders of two major genomic research centers to ask about their institutions, the challenges they’ve faced and continue to face, and how others can make the move to personalized medicine and contribute to the next evolution in healthcare.
False
Explore More in Pathology
Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.
False
False
Related Content
A Helping Hand from AI in Prostate Cancer Diagnostics
February 8, 2022
3 min read
Using AI to enhance personalized healthcare for patients with prostate cancer
The Ultimate Vision for Rare Disease
February 28, 2022
1 min read
Genomics and computational pathology can take rare disease diagnostics to the next level
A Light in the Darkness
March 4, 2022
1 min read
Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics
In-House Matters
April 7, 2022
1 min read
Molecular pathology is complex – and the benefits of keeping it local are extensive